심혈관 기기 시장 : 기기 유형, 액세스 방법, 시술 유형, 소재 유형, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Cardiovascular Devices Market is projected to grow by USD 109.79 billion at a CAGR of 8.06% by 2032.

Cardiovascular Devices Market Introduction

Cardiovascular devices remain central to modern care because cardiovascular disease is the world's leading cause of death. The World Health Organization estimates that cardiovascular diseases account for approximately 17.9 million deaths each year, while the CDC reports that heart disease is the leading cause of death in the United States. This sustained clinical burden is driving demand for diagnostic, interventional, surgical, rhythm management, structural heart, vascular access, hemodynamic support, and remote cardiac monitoring technologies.

The cardiovascular devices market is being shaped by aging populations, rising hypertension, obesity, and diabetes prevalence, earlier diagnosis, and the shift from open procedures to minimally invasive and catheter-based cardiovascular interventions. Hospitals, ambulatory surgical centers, cardiac catheterization laboratories, and connected-care programs are prioritizing medical devices that shorten length of stay, reduce readmissions, improve procedural precision, support guideline-based care, and generate clinically useful data across the patient journey.

Transformative Shifts in the Cardiovascular Devices Landscape

The cardiovascular devices landscape is moving from episodic intervention toward integrated, data-enabled cardiovascular care. Structural heart devices, drug-eluting stents, transcatheter valve systems, electrophysiology tools, cardiac rhythm management devices, ventricular assist devices, vascular closure devices, and wearable cardiac monitors are increasingly evaluated not only on procedural success but also on total cost of care, patient safety, and long-term clinical outcomes.

Regulatory and reimbursement expectations are also transforming the sector. The U.S. FDA's continued emphasis on real-world evidence, the European Union Medical Device Regulation's stricter clinical evidence requirements, and growing payer scrutiny are raising the bar for safety, traceability, post-market surveillance, cybersecurity, and health economic value. As a result, manufacturers are investing in clinical differentiation, resilient supply chains, software validation, human factors engineering, and lifecycle evidence generation.

Cumulative Impact of Artificial Intelligence on Cardiovascular Devices

Artificial intelligence is creating cumulative value across cardiovascular devices by improving signal interpretation, imaging workflows, risk stratification, triage, and remote patient monitoring. FDA-cleared AI-enabled medical technologies have expanded rapidly in recent years, with cardiovascular applications represented across ECG analytics, echocardiography support, CT-based assessment, arrhythmia detection, coronary imaging, and clinical decision support.

The most important impact is not a single algorithm but the compounding effect of AI across cardiovascular device ecosystems. AI can help detect atrial fibrillation earlier, prioritize high-risk patients, automate measurements, reduce operator variability, support continuous monitoring after discharge, and improve workflow efficiency in high-volume cardiac settings. However, adoption depends on validated performance across diverse populations, transparent model governance, cybersecurity controls, interoperability with clinical systems, workflow integration, and reimbursement pathways that reward measurable clinical benefit.

Key Regional Insights for Cardiovascular Devices

Asia-Pacific is a high-opportunity cardiovascular devices region due to large patient populations, expanding insurance coverage, rising noncommunicable disease burden, and rapid hospital infrastructure development across China, India, Japan, South Korea, Australia, and Southeast Asia. Japan and Australia remain mature, quality-driven markets with strong clinical governance, while China and India are scaling domestic manufacturing, catheterization capacity, cardiac surgery access, and interventional cardiology services. Southeast Asian health systems are also expanding cardiac care capabilities through public investment, private hospital growth, and medical tourism-oriented centers of excellence.

North America continues to lead in premium cardiovascular device adoption, clinical trials, digital health integration, and early commercialization, supported by advanced electrophysiology, structural heart, heart failure management, and remote monitoring programs. Europe remains a major innovation and regulatory hub, although compliance with EU MDR is reshaping product portfolios, documentation requirements, and clinical evidence strategies. Latin America shows growing demand in Brazil and Mexico but remains influenced by public procurement cycles, reimbursement variability, and uneven access to specialized cardiac services. The Middle East, especially GCC health systems, is investing in tertiary cardiac care, digital hospitals, and specialist workforce capacity, while Africa presents long-term access opportunities tied to infrastructure investment, workforce development, affordable device models, and stronger referral networks for cardiovascular disease management.

Key Group Insights Across Strategic Market Blocs

ASEAN is emerging as an important growth corridor as Indonesia, Vietnam, Thailand, Malaysia, Singapore, and the Philippines expand cardiac care capacity, private hospital networks, and access to interventional procedures. Singapore acts as a regional clinical, training, and distribution hub, while larger ASEAN markets are focused on affordability, public-private partnerships, localized service networks, and improved access to diagnostic and therapeutic cardiovascular devices.

The GCC is investing heavily in specialty cardiovascular centers, digital health infrastructure, and premium medical technologies aligned with national health transformation programs. The European Union is defined by strong clinical standards, centralized regulatory obligations under EU MDR, health technology assessment scrutiny, and demand for evidence-backed cardiovascular innovation. BRICS economies combine significant cardiovascular disease burden with manufacturing scale, public procurement influence, and pricing pressure, creating opportunities for value-engineered devices and localized production. G7 markets remain benchmarks for advanced adoption, reimbursement evidence, clinical guideline influence, and premium innovation, while NATO-aligned healthcare and procurement environments increasingly emphasize supply chain resilience, cybersecurity, device traceability, and trusted medical technology sourcing.

Key Country Insights in Cardiovascular Devices

The United States is a major innovation and commercialization platform for cardiovascular devices, supported by high procedure volumes, FDA regulatory pathways, Medicare coverage influence, and strong adoption of rhythm management, structural heart, electrophysiology, ambulatory diagnostics, and remote monitoring technologies. Canada offers a publicly funded, evidence-driven environment with emphasis on clinical value and equitable access, while Mexico combines private hospital demand with proximity to North American manufacturing and supply networks. Brazil is Latin America's largest cardiovascular care opportunity by population scale, driven by expanding interventional cardiology and hospital modernization, although reimbursement complexity and public procurement variability remain important considerations.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major cardiovascular care markets with strong specialist networks, guideline-based treatment pathways, and established hospital systems, with Germany standing out for hospital infrastructure and procedural capacity. Russia has demand for advanced cardiac technologies but faces procurement, sanctions, localization, and supply chain constraints. China is scaling domestic innovation, local procurement, and high-volume cardiovascular intervention capacity; India is expanding access through affordability-focused care models and growing tertiary hospitals; Japan emphasizes quality, safety, and aging-related cardiovascular care; Australia supports high-standard clinical adoption within a regulated health system; and South Korea combines advanced hospitals with strong medical technology, digital health capability, and rapid adoption of connected cardiovascular care.

Actionable Recommendations for Cardiovascular Device Leaders

Industry leaders should prioritize differentiated clinical evidence rather than incremental feature claims. Cardiovascular devices that demonstrate reduced complications, shorter hospitalization, better adherence, lower readmissions, improved procedural efficiency, or improved long-term outcomes are better positioned with providers, payers, and clinical decision-makers.

Executives should build AI governance, cybersecurity, interoperability, usability testing, and post-market surveillance into product strategy from the start. Companies should also diversify manufacturing, strengthen regional distribution and service partnerships, design value-tiered cardiovascular device portfolios for emerging markets, and align market access teams with real-world evidence generation. In high-priority categories such as structural heart, electrophysiology, heart failure monitoring, vascular intervention, and ambulatory cardiac diagnostics, partnerships with hospitals, digital health platforms, academic centers, and contract manufacturers can improve speed, scalability, and clinical relevance.

Research Methodology

This executive summary applies a structured secondary and analytical research methodology aligned with established market intelligence practices. Inputs include publicly available data from authoritative sources such as the WHO, CDC, FDA, OECD, Eurostat, national health agencies, regulatory databases, clinical guidelines, peer-reviewed literature, hospital and payer publications, and public medical technology disclosures.

The analysis triangulates cardiovascular disease burden, procedure adoption, regulatory changes, reimbursement dynamics, technology trends, AI adoption patterns, and regional market conditions. Qualitative interpretation is used to assess adoption barriers, investment priorities, clinical evidence expectations, and strategic positioning, while avoiding unsupported market sizing, market share, or forecasting claims. Insights are validated through consistency checks across clinical, regulatory, economic, and operational evidence sources.

Conclusion

The cardiovascular devices market is entering a more connected, evidence-intensive era. Demand is supported by the persistent global burden of cardiovascular disease, aging populations, and the clinical shift toward minimally invasive intervention, continuous monitoring, AI-enabled diagnostics, and personalized cardiovascular care.

Winners will be organizations that combine clinically meaningful innovation with regulatory discipline, AI-enabled intelligence, robust cybersecurity, interoperable data systems, and scalable access models. As providers and payers focus on outcomes, cardiovascular device manufacturers must prove value across the full care pathway, from diagnosis and intervention to recovery, monitoring, and long-term disease management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiovascular Devices Market, by Device Type

• 7.1. Diagnostic & Monitoring Devices
  • 7.1.1. ECG Systems
  • 7.1.2. Electrode Leads & Accessories
  • 7.1.3. Event Monitors
  • 7.1.4. Holter Monitors
  • 7.1.5. Implantable Loop Recorders
• 7.2. Surgical Devices
  • 7.2.1. Cardiac Stents
  • 7.2.2. Catheters
  • 7.2.3. Heart Valves
  • 7.2.4. Vascular Grafts
• 7.3. Therapeutic Devices
  • 7.3.1. Blood Pressure Monitors
  • 7.3.2. Defibrillators
  • 7.3.3. Pacemakers

8. Cardiovascular Devices Market, by Access Type

• 8.1. Transcutaneous
• 8.2. Transvenous

9. Cardiovascular Devices Market, by Procedure Type

• 9.1. Interventional Cardiology Procedures
• 9.2. Electrophysiology Procedures
• 9.3. Cardiac Surgery
• 9.4. Structural Heart Procedures

10. Cardiovascular Devices Market, by Material Type

• 10.1. Metal-based Devices
• 10.2. Polymer-based Devices
• 10.3. Bioresorbable Materials

11. Cardiovascular Devices Market, by Application

• 11.1. Cardiac Rhythm Management
• 11.2. Coronary Artery Disease
• 11.3. Peripheral Vascular Disease
• 11.4. Stroke Management

12. Cardiovascular Devices Market, by End User

• 12.1. Ambulatory Surgical Centers
• 12.2. Home Care
• 12.3. Hospitals & Clinics

13. Cardiovascular Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Cardiovascular Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cardiovascular Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. ACS Diagnostics
• 17.3. Alivecor, Inc.
• 17.4. Asahi Kasei Corporation
• 17.5. B. Braun SE
• 17.6. Baxter International Inc.
• 17.7. Bexen Medical
• 17.8. Biotronik SE & Co KG
• 17.9. Boston Scientific Corporation
• 17.10. BPL Medical Technologies Private Limited
• 17.11. Edwards Lifesciences Corporation
• 17.12. GE Healthcare
• 17.13. HeartFlow Holding, Inc.
• 17.14. Johnson & Johnson Services, Inc.
• 17.15. Koninklijke Philips N.V.,
• 17.16. Lepu Medical Technology(Beijing)Co.,Ltd.
• 17.17. LivaNova PLC
• 17.18. Medtronic PLC
• 17.19. Microport Scientific Corporation
• 17.20. Nihon Kohden Corporation
• 17.21. Schiller AG
• 17.22. Siemens Healthineers
• 17.23. Terumo Cardiovascular Systems Corporation
• 17.24. Tricog Health
• 17.25. Vesalius Cardiovascular Inc.
• 17.26. Zoll Medical Corporation